The expanded interchangeability now applies to the 40mg prefilled syringe and the 40mg and 80mg autoinjectors, in addition to the 20mg and 80mg prefilled syringes. The Food and Drug Administration ...
Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...
Autoinjector recognized by the Arthritis Foundation with Ease of Use Certification Individualized patient support program “HADLIMA For You” available including co-pay support Designed to improve ...
Please provide your email address to receive an email when new articles are posted on . Hadlima was approved as a biosimilar to Humira in 2019. The drug is available in a pre-filled syringe or a ...
In the last month, the FDA has granted interchangeability status to additional adalimumab biosimilars. Biosimilars with an interchangeable designation may be substituted for the reference product at ...
The Food and Drug Administration has designated Celltrion’s Yuflyma (adalimumab-aaty), as an interchangeable biosimilar to Abbvie's Humira (adalimumab). Yuflyma is a high-concentration (100mg/ml) and ...
The US Food and Drug Administration (FDA) has approved the high-concentration, citrate-free formulation of adalimumab-adbm (Cyltezo), a biosimilar of Humira, Boehringer Ingelheim announced. This ...
Uncertainties remain about the real-world benefit of adalimumab biosimilars for psoriasis, limiting their widespread adoption. This analysis involving patients in the U.K. and Ireland provides ...
If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor. Starting July 1, alternatives to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback